g5 mobile cgm system dg5  (Dexcom Inc)

Journal: Journal of Diabetes Science and Technology

Article Title: Performance and Usability of Three Systems for Continuous Glucose Monitoring in Direct Comparison

doi: 10.1177/1932296819826965

Figure Lengend Snippet: Characteristics of the Three Continuous Glucose Monitoring (CGM) Systems as Used in the Study.

Article Snippet: Dexcom G5 Mobile CGM system (DG5) , Dexcom Inc, San Diego, CA, USA , 7 days , 2 h after sensor insertion; then every 12 h a , 40-400 mg/dL , Dexcom G5 Mobile receiver b , 5222281 (2017-12-07).

Techniques:

Journal: Journal of Diabetes Science and Technology

Article Title: Performance and Usability of Three Systems for Continuous Glucose Monitoring in Direct Comparison

doi: 10.1177/1932296819826965

Figure Lengend Snippet: Characteristics of the Three Continuous Glucose Monitoring (CGM) Systems as Used in the Study.

Article Snippet: Device data were downloaded using the respective associated software. table ft1 table-wrap mode="anchored" t5 Table 1. caption a7 Name Manufacturer Sensor life time Calibration pattern Measuring range Data display Sensor lot (expiry date) Dexcom G5 Mobile CGM system (DG5) Dexcom Inc, San Diego, CA, USA 7 days 2 h after sensor insertion; then every 12 h a 40-400 mg/dL Dexcom G5 Mobile receiver b 5222281 (2017-12-07) Guardian Connect System (GC) Medtronic MiniMed Inc, Northridge, CA, USA 6 days 2 h after sensor insertion, 5 h after sensor insertion; then every 12 h a 40-400 mg/dL Smart device (iPod Touch) D107P (2017-10-07), D177P (2017-10-14) Roche CGM System c (RCGM) Roche Diabetes Care GmbH, Mannheim Germany 7 days 2 h after sensor insertion, within 5 h after sensor insertion; then after every 12 h d 40-400 mg/dL Smartphone (HTC One M7) 30000430 (2017-12-31) Open in a separate window a And if requested by system. b Smart device possible according to manual. c Not available on the market. d No later than every 14 h according to manual.

Techniques:

Journal: Diabetes Technology & Therapeutics

Article Title: Measurement Performance of Two Continuous Tissue Glucose Monitoring Systems Intended for Replacement of Blood Glucose Monitoring Parts of the data have previously been presented at the 77th Scientific Sessions of the American Diabetes Association in San Diego, CA; June 9–13, 2017 and at the 17th Annual Diabetes Technology Meeting in Bethesda, MD, November 2–4, 2017. Trial number: DRKS00011920; registered at the Deutsches Register Klinischer Studien (German clinical trials register), an approved Primary Register in the WHO International Clinical Trials Registry Platform.

doi: 10.1089/dia.2018.0105

Figure Lengend Snippet: Performance Parameters for the Dexcom G5 Mobile System and the FreeStyle Libre System When Compared Against BGMS Results Based on Aggregated Data

Article Snippet: Recently, the Dexcom G5 ® (DG5) Mobile (Dexcom, Inc., San Diego, CA), a real-time CGM (rtCGM) system, and the FreeStyle Libre (FL; Abbott Diabetes Care, Alameda, CA) system, a so-called flash glucose monitoring system, were approved by the Food and Drug Administration (FDA) for replacement of BG measurements, that is, for nonadjunctive use, with some exceptions as mentioned in the devices' labeling.

Techniques:

Journal: Diabetes Technology & Therapeutics

Article Title: Measurement Performance of Two Continuous Tissue Glucose Monitoring Systems Intended for Replacement of Blood Glucose Monitoring Parts of the data have previously been presented at the 77th Scientific Sessions of the American Diabetes Association in San Diego, CA; June 9–13, 2017 and at the 17th Annual Diabetes Technology Meeting in Bethesda, MD, November 2–4, 2017. Trial number: DRKS00011920; registered at the Deutsches Register Klinischer Studien (German clinical trials register), an approved Primary Register in the WHO International Clinical Trials Registry Platform.

doi: 10.1089/dia.2018.0105

Figure Lengend Snippet: Deviations (differences and relative differences) between continuous tissue glucose monitoring readings and blood glucose monitoring system results at times of therapeutic decisions. (A) Aggregated data. (B) Box plots of application-site-specific percentages ( n = 40 per plot); whiskers represent minimum and maximum values. DG5, Dexcom G5; FL, FreeStyle Libre; LOCF, last observed carried forward.

Article Snippet: Recently, the Dexcom G5 ® (DG5) Mobile (Dexcom, Inc., San Diego, CA), a real-time CGM (rtCGM) system, and the FreeStyle Libre (FL; Abbott Diabetes Care, Alameda, CA) system, a so-called flash glucose monitoring system, were approved by the Food and Drug Administration (FDA) for replacement of BG measurements, that is, for nonadjunctive use, with some exceptions as mentioned in the devices' labeling.

Techniques: